APO Research
Talk to an analyst

APO RESEARCH · REPORT

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025174 pages

Choose your research edition.

Industry ResearchIdiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Research Report 2026100 pages · $2,950 USDIndustry Growth & TrendsGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics include Grifols Biologicals Inc., Amgen Inc, GlaxoSmithKline Plc and Roch, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Company

Grifols Biologicals Inc.

Amgen Inc

GlaxoSmithKline Plc

Roch

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Type

Thrombopoietin Receptor Agonists (TPO-RA)

Corticosteroids

Anti-D Immunoglobulin

Intravenous Immunoglobulin (IVIG)

Others

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Application

Hospitals

Clinics

Others

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics industry.

Chapter 3: Detailed analysis of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Idiopathic Thrombocytopenic Purpura (ITP) Therapeuticsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Thrombopoietin Receptor Agonists (TPO-RA) Table 3. Key Players of Corticosteroids Table 4. Key Players of Anti-D Immunoglobulin Table 3. Key Players of Intravenous Immunoglobulin (IVIG) Table 4. Key Players of Others Table 5. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Hospitals Table 7. Key Players of Clinics Table 8. Key Players of Others Table 9. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Region (2021-2026) Table 12. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Region (2027-2032) Table 14. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Trends Table 15. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Drivers Table 16. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Opportunities and Challenges Table 17. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Restraints Table 18. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Company (2021-2026) Table 20. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Key Company Head Office and Area Served Table 22. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company, Product Type & Application Table 23. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Type (2021-2026) Table 30. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Type (2027-2032) Table 31. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application (2021-2026) Table 35. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application (2027-2032) Table 36. Grifols Biologicals Inc. Company Information Table 37. Grifols Biologicals Inc. Business Overview Table 38. Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 40. Grifols Biologicals Inc. Recent Development Table 41. Amgen Inc Company Information Table 42. Amgen Inc Business Overview Table 43. Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 45. Amgen Inc Recent Development Table 46. GlaxoSmithKline Plc Company Information Table 47. GlaxoSmithKline Plc Business Overview Table 48. GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 50. GlaxoSmithKline Plc Recent Development Table 51. Roch Company Information Table 52. Roch Business Overview Table 53. Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 55. Roch Recent Development Table 56. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 57. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 58. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 59. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 60. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 61. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021-2026) Table 62. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2027-2032) Table 63. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 64. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 65. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 66. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 67. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 68. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021-2026) Table 69. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2027-2032) Table 70. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 71. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 72. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 73. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 74. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 75. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 76. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 77. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 78. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021-2026) Table 80. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2027-2032) Table 81. South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 82. South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 83. South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 84. South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 85. South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021-2026) Table 87. South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2027-2032) Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Image Figure 2. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type: 2025 VS 2032 Figure 4. Thrombopoietin Receptor Agonists (TPO-RA) Image Figure 5. Corticosteroids Image Figure 6. Anti-D Immunoglobulin Image Figure 7. Intravenous Immunoglobulin (IVIG) Image Figure 8. Others Image Figure 9. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application: 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Clinics Image Figure 13. Others Image Figure 14. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 16. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Type (2021-2032) Figure 23. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application (2021-2032) Figure 25. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 26. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type (2021-2032) Figure 27. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application (2021-2032) Figure 28. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Country (2021-2032) Figure 29. United States Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 30. Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 32. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 33. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type (2021-2032) Figure 34. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application (2021-2032) Figure 35. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Country (2021-2032) Figure 36. Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 37. France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 39. Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 40. Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 42. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 43. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type (2021-2032) Figure 44. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application (2021-2032) Figure 45. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 46. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type (2021-2032) Figure 47. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application (2021-2032) Figure 48. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Country (2021-2032) Figure 49. Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 53. India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 54. Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Country (2021-2032) Figure 59. Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 64. UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 66. Chile Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Thrombopoietin Receptor Agonists (TPO-RA)
  • Corticosteroids
  • Anti-D Immunoglobulin
  • Intravenous Immunoglobulin (IVIG)
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Grifols Biologicals Inc.
  • Amgen Inc
  • GlaxoSmithKline Plc
  • Roch

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Thrombopoietin Receptor Agonists (TPO-RA)
  5. 1.2.3 Corticosteroids
  6. 1.2.4 Anti-D Immunoglobulin
  7. 1.2.5 Intravenous Immunoglobulin (IVIG)
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Clinics
  13. 1.3.4 Others
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Growth Trends by Region
  16. 1.5.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2021-2026)
  18. 1.5.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Dynamics
  1. 2.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Trends
  2. 2.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Drivers
  3. 2.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Company (2021-2026)
  2. 3.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Key Company Head office and Area Served
  4. 3.4 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company, Product Type & Application
  5. 3.5 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Tier 1, Tier 2, and Tier 3
4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Type
  1. 4.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2032)
  3. 4.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Share by Type (2021-2032)
5 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Application
  1. 5.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2032)
  3. 5.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Grifols Biologicals Inc.
  2. 6.1.1 Grifols Biologicals Inc. Company Information
  3. 6.1.2 Grifols Biologicals Inc. Business Overview
  4. 6.1.3 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  6. 6.1.5 Grifols Biologicals Inc. Recent Developments
  7. 6.2 Amgen Inc
  8. 6.2.1 Amgen Inc Company Information
  9. 6.2.2 Amgen Inc Business Overview
  10. 6.2.3 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  12. 6.2.5 Amgen Inc Recent Developments
  13. 6.3 GlaxoSmithKline Plc
  14. 6.3.1 GlaxoSmithKline Plc Company Information
  15. 6.3.2 GlaxoSmithKline Plc Business Overview
  16. 6.3.3 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  18. 6.3.5 GlaxoSmithKline Plc Recent Developments
  19. 6.4 Roch
  20. 6.4.1 Roch Company Information
  21. 6.4.2 Roch Business Overview
  22. 6.4.3 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  24. 6.4.5 Roch Recent Developments
7 North America
  1. 7.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032)
  2. 7.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type
  3. 7.2.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2026)
  4. 7.2.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2027-2032)
  5. 7.2.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type (2021-2032)
  6. 7.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application
  7. 7.3.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2026)
  8. 7.3.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2027-2032)
  9. 7.3.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application (2021-2032)
  10. 7.4 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country
  11. 7.4.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021-2026)
  13. 7.4.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2027-2032)
  14. 7.4.4 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032)
  2. 8.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type
  3. 8.2.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2026)
  4. 8.2.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2027-2032)
  5. 8.2.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type (2021-2032)
  6. 8.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application
  7. 8.3.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2026)
  8. 8.3.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2027-2032)
  9. 8.3.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application (2021-2032)
  10. 8.4 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country
  11. 8.4.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021-2026)
  13. 8.4.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2027-2032)
  14. 8.4.4 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032)
  2. 9.2 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type
  3. 9.2.1 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2026)
  4. 9.2.2 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2027-2032)
  5. 9.2.3 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type (2021-2032)
  6. 9.3 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application
  7. 9.3.1 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2026)
  8. 9.3.2 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2027-2032)
  9. 9.3.3 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032)
  2. 10.2 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type
  3. 10.2.1 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2026)
  4. 10.2.2 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2027-2032)
  5. 10.2.3 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type (2021-2032)
  6. 10.3 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application
  7. 10.3.1 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2026)
  8. 10.3.2 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2027-2032)
  9. 10.3.3 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application (2021-2032)
  10. 10.4 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country
  11. 10.4.1 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021-2026)
  13. 10.4.3 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2027-2032)
  14. 10.4.4 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst